MergerAug 6, 2026, 04:30 PM
NextCure Announces Merger with Avere, Reports Q2 2026 Results
AI Summary
NextCure, Inc. announced a definitive merger agreement with Avere Therapeutics, a privately held biotechnology company, in an all-stock transaction. Concurrently, Avere secured a private financing expected to generate approximately $320 million. NextCure also reported its second quarter 2026 financial results, showing cash, cash equivalents, and marketable securities of $20.1 million, a net loss of $14.9 million, and $5.1 million in asset impairment costs. The company is preserving capital and restructuring in anticipation of the merger, which is expected to close in the second half of 2026.
Key Highlights
- Announced definitive merger agreement with Avere Therapeutics in an all-stock transaction.
- Avere Therapeutics secured private financing expected to generate approximately $320 million.
- Cash, cash equivalents, and marketable securities were $20.1 million as of June 30, 2026.
- Research and development expenses decreased to $7.4 million for Q2 2026 from $24.1 million in Q2 2025.
- General and administrative expenses decreased to $2.6 million for Q2 2026 from $3.2 million in Q2 2025.
- Asset impairment costs totaled $5.1 million in the second quarter of 2026.
- Net loss was $14.9 million for Q2 2026, compared to $26.8 million for Q2 2025.
- Existing NextCure stockholders are expected to receive contingent value rights (CVRs).
Price Impact
More from NXTC